To provide a conceptual overview of the therapeutic mechanism, we illustrated a schematiccomparison between the fibrotic signaling pathways observed in systemic sclerosis and those modulated by A20 mRNA treatment (Figure 6). This evidence concerns the gene TNFAIP3 and systemic sclerosis.